Patents
The VASCADE® product is covered by one or more of the following US patents:
- US 5,782,860
- US 5,922,009
- US 6,056,769
- US 7,691,127
- US 8,747,435
- US 8,911,472
- US 9,439,637
The CATALYST® II product is covered by one or more of the following US patents:
- US 5,782,860
- US 5,922,009
- US 6,056,769
- US 7,691,127
- US 7,993,366
- US 9,179,897
- US 9,597,066
The CATALYST® III product is covered by one or more of the following US patents:
- US 5,782,860
- US 5,922,009
- US 6,056,769
- US 7,691,127
- US 7,993,366
- US 8,747,435
Cardiva Company Milestones
VASCADE MVP® receives FDA approval for 6-12F Inner Diameter (ID) multi-vessel venous vascular closure
Antegrade Study results published in Vascular Disease Management in 2018
VASCADE® receives FDA approval for use in femoral veins in 2018
VASCADE VCS approved by the FDA in 2013
VASCADE VCS approved for CE Mark in Europe in 2012
CATALYST III received 510(k) clearance in 2009
CATALYST II approved for CE Mark in Europe in 2008
CATALYST II received 510(k) clearance in 2007